Welcome to our dedicated page for Cerenome news (Ticker: CNSY), a resource for investors and traders seeking the latest updates and insights on Cerenome stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cerenome's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cerenome's position in the market.
Cerenome (CNSY) announced that its wholly owned subsidiary CNSide Diagnostics has appointed Samantha Fowlkes as Vice President and Head of Commercial Sales, effective with the September 16, 2026 announcement. She will lead the commercial expansion of the CNSide® cerebrospinal fluid–based diagnostics platform, focusing on adoption among oncologists, pathologists, physicians, and health systems.
Fowlkes brings more than 20 years of commercial leadership in oncology diagnostics, precision medicine and laboratory services, most recently as Vice President, U.S. Head of Client Clinical Operations at Caris Life Sciences, with prior roles at Genoptix Medical Laboratory and Laboratory Corporation of America. Cerenome is a CNS oncology company with the CNSide® diagnostics platform and the REYOBIQ™ therapeutic platform, which is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancers.
Cerenome (CNSY) entered a senior secured financing agreement with 3i Fund for a facility of up to $20 million with royalty-based repayments.
The company received an initial tranche at closing, with additional tranches contingent on achieving specified milestones. Proceeds are intended to support commercial scale-up and development of the CNSide cerebrospinal fluid assay platform and other proprietary laboratory-developed tests. Cerenome describes the structure as designed to be minimally dilutive to stockholders while funding CNSide sales growth and pipeline expansion. The company now forecasts its cash runway to extend well into 2028, based on this facility, other existing facilities, current cash, and expected CNSide-related sales and cash flow.
Cerenome (Nasdaq: CNSY) reported new data from two posters at the 2026 SNO/ASCO CNS Metastases Conference covering its REYOBIQ™ radiotherapeutic program and CNSide® diagnostics-driven care model for leptomeningeal metastases (LM).
Updated ReSPECT-LM and ongoing ReSPECT-LMM results showed pharmacokinetic, pharmacodynamic and dosimetry findings for REYOBIQ, including rapid cerebrospinal fluid (CSF) redistribution, a 1.7-hour ventricular half-life, apoptosis gene induction within about 5 hours, and no dose-limiting toxicities in Cohort 1a of the repeated-dosing study. A separate CNSide cost-of-care model estimated average LM treatment costs at about $119,550 per month and suggested a CNSide-enabled pathway could reduce monthly LM-related costs by roughly 33–47% under modeled scenarios.
Cerenome (Nasdaq: CNSY) reported second quarter 2026 results and a business update, including its rebranding from Plus Therapeutics effective August 3, 2026 and continued Nasdaq listing under ticker CNSY. The company advanced REYOBIQ clinical programs in leptomeningeal metastases (ReSPECT-LM), recurrent glioblastoma (ReSPECT-GBM) and pediatric brain cancer (ReSPECT-PBC), with no dose-limiting toxicities observed in ReSPECT-LM and first ReSPECT-PBC dosing expected in Q3 2026.
Cerenome’s CNSide CSF assay platform performed 232 tests in the first half of 2026, achieved contracted commercial payer coverage of 150 million lives by mid-year, obtained Medicare and AMA billing identifiers, and earned CAP accreditation. Cash, cash equivalents and investments totaled $8.6 million at June 30, 2026, unchanged from December 31, 2025.
Q2 2026 grant revenue was $0.4 million, operating loss $9.1 million and net loss $9.0 million, versus Q2 2025 net income of $5.2 million that included a $6.5 million favorable derivative fair value change.
Cerenome (Nasdaq:CNSY) announced that its subsidiary CNSide Diagnostics signed an in-network provider agreement with Health Care Service Corporation (HCSC), effective August 1, 2026, for the CNSide® cerebrospinal fluid Tumor Cell Enumeration assay. HCSC represents about 27.3 million commercial and Medicare Advantage covered lives.
Combined with prior contracts, CNSide now has contracted access to approximately 153 million covered lives, exceeding Cerenome’s full-year 2026 commercial and Medicare Advantage coverage objective of 150 million lives. According to Cerenome, CNSide’s clinical utility has been supported by 12 peer-reviewed publications, the FORESEE study, and over 11,000 tests performed at more than 120 U.S. cancer institutions since 2020.
Cerenome (Nasdaq: CNSY) announced that its wholly owned subsidiary, CNSide Diagnostics, has selected XiFin Empower RCM to provide billing and clearinghouse services for the CNSide cerebrospinal fluid assay platform. Cerenome expects to begin billing through XiFin in Q3 2026, including an accumulated backlog of CNSide tests.
According to Cerenome, XiFin’s AI-driven platform offers end-to-end revenue cycle capabilities and scalable automation to support higher test volumes without proportional administrative cost. The move follows expanded commercial and Medicare Advantage payer coverage for CNSide and is intended to help improve claim quality, reduce days sales outstanding, and support revenue and profitability goals.